Peer-influenced content. Sources you trust. No registration required. This is HCN.

MDLinxRealizing the Promise of Precision Oncology with an Open-source Tool

MatchMiner Accelerates Precision Medicine Adoption by Streamlining Clinical Trial Matching

Precision medicine (PM) is revolutionizing cancer treatment by offering therapies tailored to individual genetic profiles. However, low patient participation in PM trials has been a significant roadblock. MatchMiner, a novel trial matching platform, aims to overcome this challenge by efficiently connecting patients and trial investigators.

HCN Medical Memo
MatchMiner offers a promising tool to increase patient participation in PM trials, thereby accelerating the adoption of precision medicine. The platform not only streamlines the process of finding the right trials for your patients but also helps in identifying suitable patients for ongoing trials. This dual functionality could be a game-changer in advancing personalized cancer therapies.

Key Points:
  • In 2022, the FDA approved 21 precision anti-cancer treatments, including six therapies targeting CAR T-cells and 15 drugs for biomarker-defined populations.
  • MatchMiner is an open-source platform developed by the Knowledge Systems Group at Dana-Farber Cancer Institute that matches patients’ genetic and clinical information with PM trial criteria.
  • The platform offers three modes: patient-centric, trial-centric, and trial search, catering to the needs of trial investigators, patients, and oncologists.
  • A study led by Dr. Harry Klein showed that MatchMiner has increased PM trial consents by 22% and reduced the time for patient consent by 55 days.

To date, MatchMiner has curated 354 trials from the Dana-Farber Cancer Institute.

Additional Points:
  • MatchMiner uses Clinical Trial Markup Language (CTML) to encode PM trial eligibility criteria and is HIPAA-compliant.
  • The platform has been integrated into clinical workflows at various institutions, including Memorial Sloan Kettering Cancer Center and the Princess Margaret Cancer Centre.
  • Unlike other systems that rely on, MatchMiner is updated daily.
  • Other barriers to PM trial participation include low clinical awareness and various patient constraints, which MatchMiner does not address.

More on Precision Oncology

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form